Ulinastatin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ulinastatin
Accession Number
DB12038
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Ulinastatin has been investigated for the prevention of Cardiovascular Disease and Adverse Reaction to Drug.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
OR3S9IF86U
CAS number
80449-31-6

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Ulinastatin.Approved, Investigational
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Ulinastatin.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Ulinastatin.Approved, Illicit, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Ulinastatin.Experimental, Investigational
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Ulinastatin.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Ulinastatin.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Ulinastatin.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Ulinastatin.Approved, Investigational
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Ulinastatin.Approved
BoceprevirThe serum concentration of Ulinastatin can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Ulinastatin.Approved, Investigational
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Ulinastatin.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Ulinastatin.Approved
CarbamazepineThe metabolism of Ulinastatin can be increased when combined with Carbamazepine.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Ulinastatin.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Ulinastatin.Approved, Investigational, Vet Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Ulinastatin is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Ulinastatin.Approved, Investigational, Vet Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Ulinastatin.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Ulinastatin.Approved, Investigational
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Ulinastatin.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Ulinastatin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ulinastatin.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Ulinastatin.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Ulinastatin.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Ulinastatin.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Ulinastatin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Ulinastatin.Approved, Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Ulinastatin.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Ulinastatin.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Ulinastatin.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Ulinastatin.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Ulinastatin.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Ulinastatin.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Ulinastatin.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Ulinastatin.Approved, Investigational, Vet Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Ulinastatin.Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Ulinastatin.Approved
GarlicThe serum concentration of Ulinastatin can be decreased when it is combined with Garlic.Approved, Nutraceutical
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Ulinastatin.Approved
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Ulinastatin.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Ulinastatin.Experimental
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Ulinastatin.Approved, Investigational
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Ulinastatin.Experimental, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Ulinastatin.Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Ulinastatin.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Ulinastatin.Approved, Illicit
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Ulinastatin.Approved, Withdrawn
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Ulinastatin.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Ulinastatin.Investigational
PethidineThe risk or severity of adverse effects can be increased when Ulinastatin is combined with Pethidine.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Ulinastatin.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Ulinastatin.Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Ulinastatin.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Ulinastatin.Approved
St. John's WortThe metabolism of Ulinastatin can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Ulinastatin.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Ulinastatin is combined with Temsirolimus.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Ulinastatin.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Ulinastatin.Approved, Investigational
TipranavirThe serum concentration of Ulinastatin can be decreased when it is combined with Tipranavir.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Ulinastatin.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Ulinastatin.Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Ulinastatin.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with Ulinastatin.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Ulinastatin.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911274
Wikipedia
Ulinastatin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Enrolling by InvitationTreatmentAcute Respiratory Distress Syndrome (ARDS)1
2Unknown StatusTreatmentInhalation Injury1
3RecruitingTreatmentOral Mucositis (Ulcerative) Due to Radiation1
4CompletedNot AvailableAbnormal Aortic Valve1
4CompletedPreventionCardiovascular Disease (CVD)1
4CompletedTreatmentCardiopulmonary Bypass / Surgery, Cardiac1
4CompletedTreatmentCoronary Artery Occlusive Disease1
4Enrolling by InvitationTreatmentCongenital Heart Disease (CHD)1
4RecruitingTreatmentSepsis / Severe Sepsis / Shock, Septic1
4SuspendedTreatmentPancreatitis1
Not AvailableCompletedPreventionRenal Mass1
Not AvailableCompletedTreatmentHepatocellular,Carcinoma1
Not AvailableNot Yet RecruitingPreventionAcute Respiratory Distress Syndrome (ARDS) / Critical Illness1
Not AvailableRecruitingNot AvailableAdverse Reaction to Drug1
Not AvailableUnknown StatusPreventionAcute Aortic Dissection1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:14 / Updated on June 02, 2018 08:33